CA2034861A1 - Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation - Google Patents

Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation

Info

Publication number
CA2034861A1
CA2034861A1 CA002034861A CA2034861A CA2034861A1 CA 2034861 A1 CA2034861 A1 CA 2034861A1 CA 002034861 A CA002034861 A CA 002034861A CA 2034861 A CA2034861 A CA 2034861A CA 2034861 A1 CA2034861 A1 CA 2034861A1
Authority
CA
Canada
Prior art keywords
myristoyl
phenylalanine
myristoylation
treatment
illnesses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002034861A
Other languages
English (en)
French (fr)
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Servier de Medecine Translationnelle SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of CA2034861A1 publication Critical patent/CA2034861A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002034861A 1990-01-25 1991-01-24 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation Abandoned CA2034861A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR90.00834 1990-01-25
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
CA2034861A1 true CA2034861A1 (fr) 1991-07-26

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002034861A Abandoned CA2034861A1 (fr) 1990-01-25 1991-01-24 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation

Country Status (14)

Country Link
US (1) US5164414A (enExample)
EP (1) EP0443891B1 (enExample)
JP (1) JPH0717503B2 (enExample)
AT (1) ATE94387T1 (enExample)
AU (1) AU633395B2 (enExample)
CA (1) CA2034861A1 (enExample)
DE (1) DE69100364T2 (enExample)
DK (1) DK0443891T3 (enExample)
ES (1) ES2060310T3 (enExample)
FR (1) FR2657259A1 (enExample)
IE (1) IE65573B1 (enExample)
OA (1) OA09478A (enExample)
PT (1) PT96571A (enExample)
ZA (1) ZA91574B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
SG11201405413SA (en) 2012-03-30 2014-10-30 Givaudan Sa N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
CN104219964B (zh) 2012-03-30 2016-09-21 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
US10856563B2 (en) 2012-03-30 2020-12-08 Givaudan S.A. N-acyl-amino acid derivatives for improvement of the flavor profile of edible compositions
JP6320367B2 (ja) 2012-03-30 2018-05-09 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化メチオニン誘導体
JP6248092B2 (ja) 2012-03-30 2017-12-13 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化１−アミノシクロアルキルカルボン酸
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
BR122020006518B1 (pt) 2012-03-30 2022-02-22 Givaudan Sa Composição de sabor
KR102496892B1 (ko) * 2012-10-30 2023-02-06 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
EP3057448B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
EP3057446B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3057447B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I

Also Published As

Publication number Publication date
IE65573B1 (en) 1995-11-01
EP0443891B1 (fr) 1993-09-15
EP0443891A1 (fr) 1991-08-28
ES2060310T3 (es) 1994-11-16
ZA91574B (en) 1991-11-27
AU633395B2 (en) 1993-01-28
PT96571A (pt) 1991-10-15
DE69100364T2 (de) 1994-04-21
DE69100364D1 (de) 1993-10-21
OA09478A (fr) 1992-11-15
US5164414A (en) 1992-11-17
FR2657259A1 (fr) 1991-07-26
AU6998791A (en) 1991-08-01
FR2657259B1 (enExample) 1994-08-19
DK0443891T3 (da) 1993-12-27
JPH04210916A (ja) 1992-08-03
JPH0717503B2 (ja) 1995-03-01
IE910242A1 (en) 1991-07-31
ATE94387T1 (de) 1993-10-15

Similar Documents

Publication Publication Date Title
EP0443891B1 (fr) Utilisation de la N-myristoyl-(S)-phénylalanine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation
EP0499521B1 (fr) Nouveaux inhibiteurs de N-myristoyltransférase, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
TAKE et al. Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases
EP1663219B1 (fr) Derives d'indole pour le traitement de maladies liees au processus d'epissage
ITMI950812A1 (it) Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
Vaillant et al. Effectors of the mammalian plasma membrane NADH-oxidoreductase system. Short-chain ubiquinone analogues as potent stimulators
Dessolin et al. New Bicyclam− AZT Conjugates: Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with CXCR-4 Coreceptor
CA2187200A1 (en) Nadh oxidase as a target in diagnosis and therapy
EP0959881A1 (en) Synthetic methods for the preparation of indolylquinones and mono- and bis-indolylquinones prepared therefrom
Zhang et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs
Heimark et al. The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system
Hall et al. Effects of imide analogs on enzymes required for cholesterol and fatty acid synthesis
AP339A (en) Indenoindoles compounds.
Krueger et al. Interaction of flexible analogs of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and of N-methyl-4-phenylpyridinium with highly purified monoamine oxidase A and B
US5866575A (en) Method of inhibiting HIV integrase
Srivastava et al. Studies on mechanism (s) of antifertility action of gossypol in rat and hamster
EP1954288B1 (fr) Derives d'amidine et leurs applications a titre de medicament
EP0461237B1 (fr) Utilisation de derives du 9,10-dihidrophenanthrene pour la preparation d'un medicament anti-tumoral et nouveaux derives
US20080199897A1 (en) Class ii histone deacetylase whole cell enzyme assay
US20060019951A1 (en) Vacuolins
US6001840A (en) Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs
Ziegler et al. Bovine Liver Mitochondrial NAD+ Glycohydrolase: Relationship to ADP-Ribosylation and Calcium Fluxes
FR2626470A1 (fr) Depresseur de l'inhibiteur de l'(alpha)2-plasmine
JPH07508046A (ja) オルニチンデカルボキシラーゼを阻害する枝分れアミノオキシアミノアルカン誘導体
KR100400877B1 (ko) 항진균제의 검색방법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued